Investigation of antihypertensive activity of carbopol valsartan transdermal gel containing 1,8-cineole

被引:64
作者
Ahad, Abdul [2 ]
Aqil, Mohd. [1 ]
Ali, Asgar [1 ]
机构
[1] Jamia Hamdard, Fac Pharm, Dept Pharmaceut, New Delhi 110062, India
[2] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11451, Saudi Arabia
关键词
Antihypertensive activity; Transdermal gel; Valsartan; EXPERIMENTAL-DESIGN TECHNIQUE; PENETRATION ENHANCERS; IN-VITRO; DRUG-DELIVERY; PROPYLENE-GLYCOL; HUMAN VOLUNTEERS; NICARDIPINE HYDROCHLORIDE; PERCUTANEOUS PENETRATION; THERAPEUTIC SYSTEM; SKIN;
D O I
10.1016/j.ijbiomac.2013.11.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of this work was to develop a transdermal gel formulation for enhanced delivery of valsartan for the management of hypertension. Transdermal gels bearing valsartan, carbopol and 1,8cineole (penetration enhancer) were prepared and characterized for various parameters including in vitro skin permeation studies, pH, spreadability, viscosity, skin irritation potential and in vivo antihypertensive activity. Optimized valsartan gel formulation (VTGF9) showed highest transdermal flux (143.51 mu g/cm(2)/h), with an enhancement ratio of 4.53 when compared to control gel formulation (VTGF8). Incorporation of 1,8-cineole and ethanol in gel formulation enhance the permeation of valsartan significantly. Skin irritation and histopathological study revealed that the VTGF9 was safe, less irritant and well tolerable formulation for transdermal delivery. In vivo antihypertensive activity revealed that optimized VTGF9 was successful in reverting the rat BP to normal values in experimental hypertensive rats. Finally, it could be concluded that VTGF9 accentuates the flux of valsartan and is an efficient transdermal therapeutic system for delivery of valsartan. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:144 / 149
页数:6
相关论文
共 36 条
[1]   Transdermal delivery of calcium channel blockers for hypertension [J].
Ahad, Abdul ;
Al-Jenoobi, Fahad I. ;
Al-Mohizea, Abdullah M. ;
Aqil, Mohd ;
Kohli, Kanchan .
EXPERT OPINION ON DRUG DELIVERY, 2013, 10 (08) :1137-1153
[2]   Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: Statistical optimization, characterization and pharmacokinetic assessment [J].
Ahad, Abdul ;
Aqil, Mohd ;
Kohli, Kanchan ;
Sultana, Yasmin ;
Mujeeb, Mohd .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 443 (1-2) :26-38
[3]   Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan [J].
Ahad, Abdul ;
Aqil, Mohammed ;
Kohli, Kanchan ;
Sultana, Yasmin ;
Mujeeb, Mohammed ;
Ali, Asgar .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2012, 8 (02) :237-249
[4]   Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action [J].
Ahad, Abdul ;
Aqil, Mohammed ;
Kohli, Kanchan ;
Sultana, Yasmin ;
Mujeeb, Mohd ;
Ali, Asgar .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2011, 37 (05) :583-596
[5]   Interactions between Novel Terpenes and Main Components of Rat and Human Skin: Mechanistic View for Transdermal Delivery of Propranolol Hydrochloride [J].
Ahad, Abdul ;
Aqil, Mohammed ;
Kohli, Kanchan ;
Sultana, Yasmin ;
Mujeeb, Mohd ;
Ali, Asgar .
CURRENT DRUG DELIVERY, 2011, 8 (02) :213-224
[6]   Chemical penetration enhancers: a patent review [J].
Ahad, Abdul ;
Aqil, Mohammed ;
Kohli, Kanchan ;
Chaudhary, Hema ;
Sultana, Yasmin ;
Mujeeb, Mohammed ;
Talegaonkar, Sushama .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (07) :969-988
[7]   Transdermal drug delivery systems of a beta blocker: Design, in vitro, and in vivo characterization [J].
Aqil, M ;
Sultana, Y ;
Ali, A ;
Dubey, K ;
Najmi, AK ;
Pillai, KK .
DRUG DELIVERY, 2004, 11 (01) :27-31
[8]   Status of terpenes as skin penetration enhancers [J].
Aqil, Mohammed ;
Ahad, Abdul ;
Sultana, Vasmin ;
Ali, Asgar .
DRUG DISCOVERY TODAY, 2007, 12 (23-24) :1061-1067
[9]   Influence of propylene glycol and isopropyl myristate on the in vitro percutaneous penetration of diclofenac sodium from carbopol gels [J].
Arellano, A ;
Santoyo, S ;
Martín, C ;
Ygartua, P .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 7 (02) :129-135
[10]  
Asbill CS, 2000, CRIT REV THER DRUG, V17, P621